Leading brokers name 3 ASX shares to sell today

Here's why brokers are bearish on these ASX shares…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Monday I looked at three ASX shares that brokers have given buy ratings to this week.

Unfortunately, not all shares are in favour with them right now. Three that have just been given sell ratings are listed below. Here's why these brokers are bearish on these ASX shares:

A2 Milk Company Ltd (ASX: A2M)

According to a note out of Credit Suisse, its analysts have retained their sell rating but lifted their price target on this fresh milk and infant formula company's shares to $5.50. The broker has increased its earnings estimates slightly to reflect better than expected demand for infant formula. However, despite this, its earnings estimates are below consensus. In addition, the broker has concerns over its daigou sales and a lack of product differentiation. The a2 Milk share price is fetching $6.69 today.

Commonwealth Bank of Australia (ASX: CBA)

A note out of Morgans reveals that its analysts have retained their reduce rating with an improved price target of $76.00. The broker is positive on the banks and expects better than expected net interest margins, cost reductions, and buybacks to be supportive. However, due to valuation reasons, the broker is holding firm with its reduce rating on CBA's shares. It believes the multiples its shares are trading on are stretched. The CBA share price is trading at $98.77 today.

Magellan Financial Group Ltd (ASX: MFG)

Analysts at Morgan Stanley have retained their underweight rating and $39.60 price target on this fund manager's shares. According to the note, the broker sees downside risk to fund inflows in FY 2022 and doesn't believe this is being reflected in its share price. In addition to this, the broker believes its performance has been soft and notes that its shares are among the most expensive in the industry globally. The Magellan share price is trading at $53.80 on Tuesday.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Business people discussing project on digital tablet.
Broker Notes

Buy, hold, sell: James Hardie, REA Group, and Ramelius shares

Analysts have given their verdict on these shares.

Read more »

Small kid giving a thumbs up.
Broker Notes

2 ASX 200 stocks that Morgans just upgraded

These stocks have between 15% and 20% upside.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Broker Notes

6 ASX 200 shares boosted by brokers this week

Brokers have increased their ratings on CSL, NAB, Ramsay Health Care, and others this week. 

Read more »

I young woman takes a bite out of a burrito n the street outside a Mexican fast-food establishment.
Broker Notes

Buy, hold, sell: Aurizon, Car Group, Guzman y Gomez shares

Toby Grimm from Baker Young explains his views and ratings on three ASX 300 shares.

Read more »

Broker looking at the share price.
Broker Notes

Buy, hold, sell: Temple & Webster, Kelsian, Boss Energy shares

Two experts share their views on three ASX shares.

Read more »

A man in a business suit holds his coffee cup aloft as he throws his head back and laughs heartily.
Broker Notes

3 ASX 200 shares forecast to fly 30% to 40% higher

Here's the latest broker forecasts.

Read more »

A mother and her two adult daughters embrace outdoors.
Broker Notes

Buy, hold, sell: AGL Energy, Telstra, Zip shares

Here are brokers' latest verdicts on these three major ASX 200 shares.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Broker Notes

This ASX biotech could jump more than 30%, one broker says

This company's core business is performing well, the broker says.

Read more »